RxDoctor Payments Data

Paula Bunde, MD

Urology · Bloomington, INNPI 1548427123

Payments from drug & device makers

$493in general payments, 2019–2025

Across 12 payments — averaging $41.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$169
  • Axonics, Inc.$157
  • Sanofi$66
  • Astellas Pharma US Inc$48
  • C. R. Bard, Inc. & Subsidiaries$28
  • ABC Home Medical Supply, Inc.$25

What the payments were for

  • Food & beverage$493100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Boston Scientific4$169
Axonics, Inc.4$157
Sanofi1$66
Astellas Pharma US Inc1$48
C. R. Bard, Inc. & Subsidiaries1$28
ABC Home Medical Supply, Inc.1$25

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$493 in reported general payments places this provider in the 15th percentile of 272 urology providers in Indiana.

See all urology providers in Indiana

Medicare billing

Part B allowed, 2024
$174,007
Medicare patients
504
Services billed
3,379

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron118$83,691
GemtesaVibegron25$28,014
Tolterodine Tartrate ErTolterodine Tartrate50$9,094
Solifenacin Succinate105$7,260
Tamsulosin Hcl346$5,373
Potassium Citrate ErPotassium Citrate35$5,184
Methenamine Hippurate45$3,258
Cefpodoxime Proxetil41$2,195
Finasteride170$2,190
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst63$2,077
Trimethoprim16$1,616
Alfuzosin Hcl ErAlfuzosin Hcl85$1,568
Silodosin13$1,228
Trospium Chloride27$1,211
Cephalexin97$924

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$48$83,691118 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 15th percentile of 272 urology providers in Indiana.

Other urology in Bloomington

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →